计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| N127052-5mg |
5mg |
现货 ![]() |
| |
| N127052-25mg |
25mg |
现货 ![]() |
| |
| N127052-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | BGJ398 (NVP-BGJ398) | 872511-34-7 (free base) | AKOS000295891 | WHO 10032 | 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea | BCP0726000187 | DB11886 | Infigratinib | Q27075200 | SCHEMBL374435 |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | BGJ398 (NVP-BGJ398) |
| 生化机理 | BGJ398 是一种强效、选择性成纤维细胞生长因子受体家族抑制剂,可抑制 Flg(FGFR-1)、Bek(FGFR-2)、FGFR-3 和 FGFR-4。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 成纤维细胞生长因子受体抑制剂 |
| 产品介绍 |
BGJ398 (NVP-BGJ398)是一种有效的,选择性的FGFR抑制剂,作用于FGFR1/2/3,IC50为0.9 nM/1.4 nM/1 nM,作用于FGFR比作用于FGFR4和VEGFR2选择性高40倍以上,对Abl, Fyn, Kit, Lck, Lyn和Yes几乎没有抑制活性。Phase 2。A potent and selective inhibitor of Flg (FGFR-1), Bek (FGFR-2), FGFR-3 and FGFR-4. BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2. |
| 纯度 | ≥98% |
| ALogP | 4.7 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea |
| INCHI | 1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31) |
| InChi Key | QADPYRIHXKWUSV-UHFFFAOYSA-N |
| Smiles | CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl |
| Isomeric SMILES | CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl |
| 分子量 | 560.48 |
| Reaxy-Rn | 12512466 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12512466&ln= |
| 溶解性 | DMSO 1 mg/mL heating (1 mM);Water <1 mg/mL (<1 mM);Ethanol <1 mg/mL (<1 mM) |
|---|---|
| 分子量 | 560.500 g/mol |
| XLogP3 | 4.700 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 8 |
| 精确质量Exact Mass | 559.187 Da |
| 单同位素质量Monoisotopic Mass | 559.187 Da |
| 拓扑极表面积Topological Polar Surface Area | 95.100 Ų |
| 重原子数Heavy Atom Count | 38 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 724.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al.. (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.. J Med Chem, 54 (20): (7066-83). [PMID:21936542] |
| 2. Komla-Ebri D, Dambroise E, Kramer I, Benoist-Lasselin C, Kaci N, Le Gall C, Martin L, Busca P, Barbault F, Graus-Porta D et al.. (2016) Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.. J Clin Invest, 126 (5): (1871-84). [PMID:27064282] |
| 3. Botrus G, Raman P, Oliver T, Bekaii-Saab T. (2021) Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.. Expert Opin Investig Drugs, 30 (4): (309-316). [PMID:33307867] |
| 4. Lee PC, Hendifar A, Osipov A, Cho M, Li D, Gong J. (2021) Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations.. Cancers (Basel), 13 (7): [PMID:33916849] [10.3390/cancers13071706] |
| 5. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T et al.. (2018) Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.. J Clin Oncol, 36 (3): (276-282). [PMID:29182496] |